Irvine-based Epiomed Therapeutics, a developer of small-molecule, anti-emetic and anti-motion sickness compounds, said this week that it raised a Series A funding round. The firm said the round came from NDI Capital. Financial details of the funding were not disclosed. The firm said the funds will go to develop its lead anti-emetic compound, used to prevent nausea and vomiting. More information »